LONDON (Alliance News) - Cardiovascular monitoring company LiDCO Group PLC on Tuesday said it has secured Chinese approval for its LiDCOrapid cardiac output monitor.
The monitor is used by hospitals for fluid and drug management, it said.
It has now been approved for commercial sale in China by the Chinese Food & Drug Administration.
"Geographical expansion remains the biggest potential driver of future growth for LiDCO and we are delighted to receive approval to sell our LiDCOrapid v2 in a growing market that presents significant opportunities for LiDCO," said LiDCO Chief Executive Matt Sassone.
LiDCO shares were untraded Tuesday morning, having last traded at 7.26 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
